Earnings Call

As TI preps its Q1 2026 earnings call, all eyes are on its performance as an indicator for the industrial, auto, and broader semiconductor sectors.

As Milestone Scientific prepares its year-end call, investors look for signs of a turnaround and growth for its advanced injection technology.

The midstream firm is refinancing debt and buying back preferred units, aiming for a simpler, more flexible financial future. What does this mean for NGL?

After a 39% stock crash, Lakeland Industries' former CFO is sued over allegedly misleading investors about the company's deteriorating financial health.

FinVolution Group is set to release its 2025 financials, with investors watching to see if international growth and AI tech can navigate market headwinds.

Fresh off a blockbuster IPO, SpyGlass Pharma heads to a key investor summit. Can its revolutionary long-acting drug platform transform chronic eye care?

The specialty finance giant posted a stunning turnaround, leveraging tech and a hot U.S. market. Here's how it plans to deliver even more in 2026.

With its stock under pressure despite strong results, Box will use a key conference to prove its AI-powered content platform is the future of enterprise work.

As VerticalScope preps its 2025 results, investors watch if its pivot to AI and e-commerce can overcome ad market and search engine challenges.

As Revvity execs prepare for key conferences, investors will watch for clues on AI strategy, growth guidance, and margin recovery after a mixed 2025.

Investors and patients await Puma Bio's Q4 results, focusing on NERLYNX sales performance and crucial updates on its promising alisertib cancer pipeline.

As BJ’s prepares to report Q4 results, investors are watching if a pizza relaunch and new efficiencies can overcome industry-wide cost pressures.

With a strong cash position, Arcus Biosciences heads into a pivotal year as investors await critical data on its promising cancer and autoimmune pipeline.

As Home Depot prepares its year-end report, investors weigh a tough consumer market against the firm's big strategic bets on pro customers and digital tools.

Amid major restructuring and a strategic asset sale, Standard BioTools' upcoming annual results will reveal its progress toward profitability in a tough market.

With strong Q3 results and key acquisitions, all eyes are on Addus HomeCare's year-end report to see if its growth momentum can be sustained.

As Omada Health preps its 2025 results, all eyes are on whether its blend of tech, human coaching, and GLP-1 support can deliver sustainable profits.

As Timbercreek Financial preps its Q4 report, investors eye dividend health and asset quality as key indicators for the broader CRE market's new cycle.

Viking Therapeutics' upcoming earnings call is about more than just financials. Investors are focused on key pipeline updates for its obesity and MASH drugs.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?